Value in Health

Value in Health
Name	Value in Health
Field	Health economics

Contents

Value in Health is a multidisciplinary construct used to assess the relative benefit of health interventions, services, and policies by comparing outcomes to costs and other inputs. It synthesizes evidence from World Health Organization, Organisation for Economic Co-operation and Development, National Institute for Health and Care Excellence, Centers for Disease Control and Prevention, and academic bodies such as Harvard University, Johns Hopkins University, University of Oxford, London School of Economics, and Karolinska Institutet. The concept informs decisions by payers, providers, regulators, and researchers, connecting clinical effectiveness, patient experience, and resource allocation across systems like Medicare (United States), National Health Service (England), and national programs in Germany, Canada, Australia, and Japan.

Definition and Conceptual Framework

Value in Health is defined through comparative frameworks advanced by actors including Michael Porter’s value-based health care propositions, frameworks from World Health Organization, and policy guidance from European Commission initiatives. It aligns with principles deployed by organizations such as Institute for Healthcare Improvement, The Commonwealth Fund, Bill & Melinda Gates Foundation, and national agencies including Agency for Healthcare Research and Quality and Canadian Agency for Drugs and Technologies in Health. The conceptual model integrates clinical outcomes used in Cochrane Collaboration reviews, patient-reported outcomes promoted by Food and Drug Administration, and quality measures from Joint Commission and National Quality Forum. Stakeholders including clinicians at institutions like Mayo Clinic, payers such as Blue Cross Blue Shield Association, and manufacturers like Pfizer or Roche interpret value within frameworks that consider long-term impact across systems like World Bank health financing projects and Gavi, the Vaccine Alliance programs.

Measurement draws on standardized indicators from International Classification of Diseases, metrics developed by EuroQol Group (EQ-5D), and methods from Global Burden of Disease studies led by Institute for Health Metrics and Evaluation. Common metrics include quality-adjusted life years (QALYs) used in guidance from National Institute for Health and Care Excellence and disability-adjusted life years (DALYs) referenced by World Health Organization. Cost metrics rely on accounting standards applied by Centers for Medicare & Medicaid Services and costing methodologies found in publications from World Bank. Comparative effectiveness research by AHRQ, health outcomes research in journals associated with American Medical Association, and registry data from European Medicines Agency inform measurement validity. Patient-centered measures are operationalized through tools endorsed by Patient-Centered Outcomes Research Institute and measurement science led by National Institutes of Health initiatives.

Economic evaluation and health technology assessment (HTA) are core to operationalizing value, employing methods from textbook authorities like Mark S. Sculpher and agencies including National Institute for Health and Care Excellence, Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, and Canadian Agency for Drugs and Technologies in Health. Techniques include cost-effectiveness analysis, cost-utility analysis, and budget-impact analysis used by European Commission HTA networks and national bodies such as Haute Autorité de Santé and Pharmaceutical Benefits Advisory Committee (Australia). Payers including Medicare (United States), NHS England, and private insurers draw on HTA evidence when negotiating price and reimbursement with manufacturers like Novartis and Johnson & Johnson. Modeling approaches referenced in guidance from International Society for Pharmacoeconomics and Outcomes Research and analytic standards from Cochrane Collaboration underpin decision rules and threshold discussions debated in fora such as World Health Assembly.

Implementing value-based approaches occurs across delivery systems like Kaiser Permanente, Intermountain Healthcare, and public programs in Sweden and Netherlands. Implementation strategies leverage payment reforms seen in Accountable Care Organization models, bundled payments piloted by Centers for Medicare & Medicaid Services, and performance-based contracting explored with manufacturers including Amgen. Health information infrastructure—including Electronic Health Records platforms promoted by Office of the National Coordinator for Health Information Technology and interoperability standards from HL7 International—supports measurement and feedback. Training and workforce development draw on curricula from Harvard Medical School, Johns Hopkins Bloomberg School of Public Health, and professional societies such as American College of Physicians and Royal College of Physicians.

Ethical and equity debates involve stakeholders like United Nations, World Health Organization, Amnesty International, and academic ethicists affiliated with Princeton University and University of Cambridge. Tensions arise when valuation frameworks from National Institute for Health and Care Excellence or Institute for Clinical and Economic Review interact with equity mandates enshrined in policy documents by European Commission or national constitutions such as German Basic Law. Distributive justice, priority-setting in pandemic influenza or COVID-19 response, and concerns about access voiced by patient advocacy groups including European Patients' Forum require adaptations of value metrics. Legal contexts shaped by rulings in jurisdictions like United States Supreme Court or legislative acts such as Affordable Care Act influence how value assessments translate into coverage and liability.

Illustrative applications include HTA decisions on oncology drugs assessed by National Institute for Health and Care Excellence and European Medicines Agency, vaccine value assessments in programs run by Gavi, the Vaccine Alliance and national immunization programs in India and Brazil, and chronic disease management initiatives at Cleveland Clinic and Geisinger Health System. Comparative examples from Rwanda health system reforms supported by World Bank projects and Partners In Health demonstrate value-driven priorities in resource-constrained settings. Innovative contracts such as outcomes-based agreements negotiated between NHS England and pharmaceutical companies, and value-based payment pilots by Centers for Medicare & Medicaid Services, illustrate operational translation of the concept across clinical areas including cardiovascular disease, oncology, and rare diseases evaluated in consortia like European Reference Networks.

Category:Health economics